Sudden cardiac death prevention study
This article was originally published in The Gray Sheet
Executive Summary
Cambridge Heart will launch a 50-center MASTER trial in early 2003 of its microvolt T-wave Alternans non-invasive test for assessing risk of SCD. The trial will examine 600 patients with previous MI and ejection fraction of 30% or less; an additional 1,200 will be enrolled in a registry of patients with ejection fraction between 30%-40%. The trial's inclusion criteria were set following the release of recent AHA/ACC guidelines (1"The Gray Sheet" Sept. 30, 2002, p. 9). Results are expected by 2005...